secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-127027
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon Q3 net loss $34.8M; cash $340M; ANX005 BLA on track for H1 2025
-----------------------------------------------------------------------

- Net loss of $34.8M ($0.25/share) vs $32.5M ($0.43) in Q3 2023.
- Cash and investments $340.1M, expected to fund operations into H2 2026.
- R&D expenses rose to $30.1M from $27.9M, driven by GBS, GA, and ANX1502 programs.
- ANX005 GBS: topline RWE comparability data expected year-end 2024; BLA submission targeted H1 2025.
- Strengthened commercial and medical affairs leadership with three senior appointments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/0000950170-24-127027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000095017024127027/annx-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-127027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer